Date: 2014-05-09
Type of information:
Acquired company: Novafarma Indústria Farmacêutica (Brazil)
Acquiring company: Fresenius Kabi (Germany)
Amount: undisclosed
Terms: * On May 9, 2014, Fresenius Kabi has entered into an agreement to acquire the privately held Brazilian pharmaceutical company Novafarma Indústria Farmacêutica Ltda. This transaction is part of Fresenius Kabi’s strategy to expand its market presence and product portfolio in emerging markets.The transaction is subject to antitrust approval in Brazil, and is expected to close in the second quarter of 2014. Fresenius Kabi entered the Brazilian market in 1977, and is one of the country\'s leading suppliers of clinical nutrition, infusion therapy and medical devices/transfusion technology. The acquisition significantly broadens Fresenius Kabi’s generic I.V. drugs portfolio for the region, and creates an excellent platform for further growth in this product segment in other Latin American countries.
Details: Novafarma offers a comprehensive range of generic I.V. drugs, including antibiotics, analgesics and anesthetics, for the Brazilian hospital market. Founded in 1992, the company is headquartered in the state of Goiás, where it also operates a manufacturing facility and a research and development center. 2013 sales were approximately €34 million.
Related:
